Compare TOP & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | GRDX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Singapore | United Kingdom |
| Employees | N/A | 2 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 39.3M |
| IPO Year | 2021 | N/A |
| Metric | TOP | GRDX |
|---|---|---|
| Price | $2.10 | $4.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 221.2K | 76.2K |
| Earning Date | 01-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,723,765.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.89 | N/A |
| 52 Week Low | $0.61 | $1.87 |
| 52 Week High | $3.33 | $6.93 |
| Indicator | TOP | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 77.70 | 44.88 |
| Support Level | $1.01 | $2.01 |
| Resistance Level | N/A | $5.30 |
| Average True Range (ATR) | 0.20 | 0.47 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 91.24 | 19.16 |
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.